Filing Details
- Accession Number:
- 0000899243-22-039056
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-19 19:22:53
- Reporting Period:
- 2022-12-15
- Accepted Time:
- 2022-12-19 19:22:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1590750 | Viridian Therapeutics Inc. | VRDN | Services-Medical Laboratories (8071) | 471187261 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1883986 | Lara Meisner | C/O Viridian Therapeutics, Inc. 221 Crescent Street, Suite 401 Waltham MA 02453 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-12-15 | 300 | $23.03 | 300 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-12-15 | 300 | $28.08 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-12-16 | 1,297 | $23.03 | 1,297 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-12-16 | 1,297 | $28.44 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-12-15 | 300 | $0.00 | 300 | $23.03 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-12-16 | 1,297 | $0.00 | 1,297 | $23.03 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
62,944 | 2031-09-22 | No | 4 | M | Direct | |
61,647 | 2031-09-22 | No | 4 | M | Direct |
Footnotes
- This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.